# 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

> **NCT02172378** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 116 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium inhalation capsules
- **DRUG:** Placebo inhalation capsules

## Key facts

- **NCT ID:** NCT02172378
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2002-01
- **Final completion:** —
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02172378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02172378, "12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02172378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*